Company intelligence / Profile preview
CohBar, Inc.
Menlo Park, California, United Statescohbar.com ↗
- Ownership
- Public · CWBR
- Employees
- ~10
- Development stage
- Other
01
Overview
CohBar was a clinical-stage biotechnology company that developed mitochondria-derived therapeutic peptides. The company had advanced CB4211 to Phase 1/2 clinical trials for NASH and was working on CB5138-3 for IPF. As of May 2025, the company is no longer operating.
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularMetabolic DisordersEndocrinologyRare Diseases
- Modalities
- Mitochondrial-derived peptide therapeuticsPeptide therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Academic institutionsPharmaceutical research centersProposed merger with Morphogenesis (announced in 2023)
Beyond the preview
Go deeper on CohBar, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CohBar, Inc..